Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.09
-0.11 (-1.77%)
Aug 14, 2025, 11:49 AM - Market open
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $163.62K in the quarter ending June 30, 2025, a decrease of -95.22%. This brings the company's revenue in the last twelve months to $423.45K, down -95.57% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$423.45K
Revenue Growth
-95.57%
P/S Ratio
238.03
Revenue / Employee
$52,932
Employees
8
Market Cap
101.86M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
COYA News
- 2 days ago - Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update - PRNewsWire
- 21 days ago - Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease - Business Wire
- 23 days ago - Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025 - Business Wire
- 2 months ago - Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025 - Business Wire
- 2 months ago - Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations - Business Wire
- 3 months ago - Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
- 3 months ago - Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
- 3 months ago - Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Business Wire